Projects

Definition and market sizing of the use cases for micro-array patches for Measles-Rubella vaccine
2019
Ongoing
Definition and market sizing of the use cases for micro-array patches for Measles-Rubella vaccine

MMGH supports the WHO's Vaccine Product & Delivery Research department in defining the use cases for a Measles Rubella vaccine micro-array patch (MAP). The use cases and their market sizes are assessed ...

Client:

World Health Organization (WHO)

Demand forecast and financial sustainability analysis for a group B streptococcal vaccine
CDC
2019
2020
Demand forecast and financial sustainability analysis for a group B streptococcal vaccine

MMGH supported the WHO Initiative for Vaccine Research (IVR) in developing a variety of forecast scenarios for the demand of a group B streptococcal (GBS) vaccine administered through maternal immunisation. ...

Client:

World Health Organization (WHO)

Advocacy for the Vaccine Against Invasive non-typhoidal Salmonella (Vacc-iNTS) project
MMGH/Carsten Mantel
2019
Ongoing
Advocacy for the Vaccine Against Invasive non-typhoidal Salmonella (Vacc-iNTS) project

MMGH is part of the Vaccine Against Invasive non-typhoidal Salmonella (Vacc-iNTS) consortium, made up of 12 partners from eight different countries including three disease-endemic countries. The initiative ...

Client:

European Commission

Operationalisation of group B streptococcal maternal vaccination
2019
2020
Operationalisation of group B streptococcal maternal vaccination

MMGH supported the WHO Initiative for Vaccine Research (IVR) in preparing a report on the considerations for operationalising group B streptococcal (GBS) maternal vaccination as part of a Public Health ...

Client:

World Health Organization (WHO)

Development of a business case for a macrofilaricide used in treatment and control of onchocerciasis
2019
2020
Development of a business case for a macrofilaricide used in treatment and control of onchocerciasis

MMGH supported the Bill & Melinda Gates Foundation in assessing the public health and financial viability of a macrofilaricide drug to accelerate the elimination of onchocerciasis. MMGH coordinated the ...

Client:

Bill & Melinda Gates Foundation

Leishmaniasis vaccine product development plan
CDC
2019
2019
Leishmaniasis vaccine product development plan

MMGH created a product development plan to guide the University of York in the further development of a candidate leishmaniasis vaccine. The plan incorporates the definition of a target product profile, ...

Client:

University of York, UK